Should I buy LivaNova (LIVN) stock or is it too late?
⭐ The most reliable of them, either direction: Mizuho — 64% of its targets hit on this sector (70 calls tested). It aims for $95 (+19 %), call made on July 16, 2026, maturing on July 16, 2027 (43 d ago).
Firm-by-firm track record on LivaNova
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| Baird | 67 % | +21.1 % | 6 | $76 -5% |
| Needham | 58 % | +11.3 % | 26 | $93 +16% |
| Stifel | 33 % | +8.1 % | 6 | $70 -13% |
| Goldman Sachs | 20 % | -1.4 % | 5 | $55 -31% |
| Mizuho | 33 % | -3.2 % | 6 | $95 +19% |
✅ Reasons to believe
- 67% of analysts rate it a buy (Buy consensus, 6 ratings) — a sign of market conviction.
- Median price target $87, i.e. +8% from the current price ($80).
⚠️ Reasons to hesitate
- Even the most reliable firm on LIVN, Baird (67% hit rate, 6 scored calls), only targets $76 (call made on May 7, 2026, maturing on May 7, 2027) (-5%) in its most recent call, and $63 (call made on November 6, 2025, maturing on November 6, 2026) (-21%) in the one coming due soonest. The stock may already have run past its target.
- The consensus is not unanimous: of 6 ratings, 2 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on LIVN
Median target $87 (+8%) · 6 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in LivaNova now?
We won't decide for you. The facts: 67% of analysts rate it a buy, median target $87 (+8%), and Baird (most reliable on LIVN, 67%) targets $76. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in LivaNova?
Not according to analysts: the median target ($87) is still +8% above the current price ($80) (most reliable on LIVN: Baird, 67%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is LivaNova still worth investing in?
It depends on the gap between the price ($80) and its estimated value: analysts target $87 on median (+8%), with 67% buys (most reliable on LIVN: Baird, 67%). Cross-check with their real reliability on LIVN and the cautions above. Information, not advice.
What's the main risk in buying LIVN?
Even the most reliable firm on LIVN, Baird (67% hit rate, 6 scored calls), only targets $76 (call made on May 7, 2026, maturing on May 7, 2027) (-5%) in its most recent call, and $63 (call made on November 6, 2025, maturing on November 6, 2026) (-21%) in the one coming due soonest. The stock may already have run past its target.
→ Go deeper: the full LivaNova profile (consensus, analyst reliability, price target, performance).